We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Development of Retinal and Brain Blood Barriers Controlled by Norrin/Frizzled4 Signaling

By LabMedica International staff writers
Posted on 27 Dec 2012
The activity of the Norrin/Frizzled4 protein pair in the embryo controls development of the retinal and brain blood barriers, and the timing of this activity is critically linked to precise blood vessel formation.

Norrin/Frizzled4 (Fz4) signaling activates the canonical Wnt pathway that controls conserved secreted signaling molecules that regulate cell-to-cell interactions during embryogenesis. More...
To determine how this signaling activity would affect the later development of the animal, investigators at Johns Hopkins University (Baltimore, MD, USA;) genetically engineered lines of mice to lack the gene for Norrin, Fz4, or for both genes. The technique that was used gave the investigators temporal and tissue-specific control of Norrin/Fz4 signaling. Other mice were engineered to express Norrin activity at an earlier stage of development than was normal.

Results published in the December 7, 2012, issue of the journal Cell revealed that early initiation of Norrin production led to premature retinal vascular invasion. Delayed Norrin production led to characteristic defects in intraretinal vascular architecture.

In the adult retina and cerebellum, gain or loss of Norrin/Fz4 signaling resulted in a cell-autonomous gain or loss, respectively, of blood retina barrier and blood-brain barrier function, indicating an ongoing requirement for Frizzled signaling in barrier maintenance and substantial plasticity in mature central nervous system vascular structure.

Although crucial to protecting the central nervous system, the blood-brain barrier also prevents drugs in the bloodstream from penetrating the brain to treat diseases. "Our research shows that blood vessel cells lacking Frizzled-4 are leaky," said senior author Dr. Jeremy Nathans, professor of molecular biology and genetics at Johns Hopkins University. "With this information in hand, we hope that someday it may be possible to temporarily loosen the blood-brain barrier, allowing life-saving drugs to pass through."

Related Links:

Johns Hopkins University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.